Compare R & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | R | ABVX |
|---|---|---|
| Founded | 1933 | 2013 |
| Country | United States | France |
| Employees | N/A | 69 |
| Industry | Rental/Leasing Companies | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 7.2B |
| IPO Year | 1994 | N/A |
| Metric | R | ABVX |
|---|---|---|
| Price | $264.74 | $99.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 13 |
| Target Price | ★ $238.56 | $131.31 |
| AVG Volume (30 Days) | 334.0K | ★ 2.4M |
| Earning Date | 04-23-2026 | 03-23-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | ★ 7.96 | N/A |
| EPS | ★ 2.33 | N/A |
| Revenue | ★ $12,665,000,000.00 | N/A |
| Revenue This Year | $5.00 | $52.14 |
| Revenue Next Year | $5.05 | $4,132.27 |
| P/E Ratio | $113.08 | ★ N/A |
| Revenue Growth | ★ 0.23 | N/A |
| 52 Week Low | $157.77 | $7.41 |
| 52 Week High | $284.25 | $148.83 |
| Indicator | R | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 54.86 | 43.82 |
| Support Level | $183.12 | $87.60 |
| Resistance Level | N/A | $131.50 |
| Average True Range (ATR) | 7.45 | 7.75 |
| MACD | -0.82 | -0.43 |
| Stochastic Oscillator | 42.87 | 46.23 |
Ryder System Inc operates in three business segments: (1) Fleet Management Solutions which provides full-service leasing and leasing with flexible maintenance options, commercial rental and maintenance services of trucks, tractors and trailers to customers; (2) Supply Chain Solutions (SCS), which provides integrated logistics solutions, including distribution management, dedicated transportation, transportation management, brokerage, e-commerce, last mile, and professional services; and (3) Dedicated Transportation Solutions (DTS), which provides turnkey transportation solutions in the U.S., including dedicated vehicles, professional drivers, management, and administrative support.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.